Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Academy, adhesion, aggressive, Amgen, anatomically, ancillary, Annex, anxiety, aplasia, arbitrage, arrythmia, Asia, ATD, autoinjector, autoreactive, axonal, backlog, batch, blockade, BNB, bona, bowel, Broadway, bulging, burden, characteristic, cheaper, CIDP, CJEU, classic, clause, constrained, corticosteroid, coupled, crystallographic, CTA, CTD, CTR, cytopenia, de, degeneration, deoxyribonucleic, dermopathy, destination, disability, disfiguring, distal, donut, drooping, EC, eCTD, electrophysiologic, eleven, energy, enjoy, enlarged, epitope, ethical, excise, explanation, fide, fold, franchise, GD, Germany, gland, GMP, goiter, gradually, hallmark, harder, heartbeat, heat, heavy, Helsinki, hepatotoxicity, hole, home, HTA, hypocalcemia, IDTA, Ig, immunomodulatory, inciting, infection, infertility, injury, insomnia, Intelligence, intolerance, ionizing, IRA, irregular, irritation, Korean, lactating, laryngeal, Lichtenstein, lifelong, linked, liver, MAA, malignancy, marrow, MDR, MEDSAFE, methimazole, mimicry, molecular, muscular, myelin, myxedema, nephrotoxicity, neurogenic, neutropenia, NOL, novo, OECD, older, outpace, overproduction, parathyroid, passage, pathophysiology, PDCO, penalize, periorbital, permeability, Pillar, play, PLEX, polysorbate, portal, pregnancy, pregnant, pretibial, PRIME, promptly, propylthiouracil, pump, radioiodine, RAI, reactive, reassigned, recession, reframing, reproductive, repurchasing, retested, revert, Ribbon, RMP, SCIg, sensorimotor, sheath, slowdown, SmPC, societal, Society, soluble, SPC, spring, strain, streamline, substantive, successor, sunset, supranational, symmetric, symmetrical, TCA, threshold, throat, thromboembolism, thyroxine, tingling, transposed, tremor, triiodothyronine, uncontrolled, understood, undesirable, unilaterally, unsafe, unstable, variation, viewpoint, washout, watched, withstand, woman
Removed:
AbbVie, agglutinin, attempted, biologically, breath, BTK, CAS, chosen, circulation, coding, cold, confirm, considerable, consummation, contrast, coordinating, decreasing, destroyed, deviation, disappearing, discontinued, distinct, divided, DNA, earnout, enabled, enjoin, female, fertility, forfeiture, Fostamatinib, founded, gained, hematologic, hemoglobin, highest, hybridoma, ibrutinib, inform, initiating, institution, irrespective, juncture, knowhow, leukemia, lieu, lymphocytic, lymphoproliferative, mammalian, mediate, menstrual, moiety, monitored, nonspecific, occurring, overactive, pharmacological, predecessor, prednisone, predominance, progression, protected, rapidly, recapitalization, recognizing, redemption, removing, renamed, repayment, rheumatoid, Rigel, roughly, run, running, score, sequester, spleen, Square, St, stabilization, steroid, subjected, subsisting, subtype, suggested, supplied, surface, syk, syndrome, tapered, temperature, temporal, tolerated, transferring, transformed, transfusion, Trump, ulceration, WAIHA, weakened, window
Filing tables
Filing exhibits
Related press release
IMVT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements of Immunovant, Inc.:
(1)Registration Statement (Form S-8 No. 333-236665) pertaining to the Immunovant, Inc. 2019 Equity Incentive Plan and the Immunovant Sciences Ltd. 2018 Equity Incentive Plan,
(2)Registration Statement (Form S-8 No. 333-239537) pertaining to the Immunovant, Inc. 2019 Equity Incentive Plan,
(3)Registration Statement (Form S-3 No. 333-251865),
(4)Registration Statement (Form S-8 No. 333-262087) pertaining to the Immunovant, Inc. 2019 Equity Incentive Plan,
(5)Registration Statement (Form S-8 No. 333-265477) pertaining to the Immunovant, Inc. 2019 Equity Incentive Plan,
(6)Registration Statement (Form S-8 No. 333-269546) pertaining to the Immunovant, Inc. 2023 Inducement Plan, and
(7)Registration Statement (Form S-8 No. 333-271138) pertaining to the Immunovant, Inc. 2019 Equity Incentive Plan;
of our report dated May 22, 2023, with respect to the consolidated financial statements of Immunovant, Inc. included in this Annual Report (Form 10-K) of Immunovant, Inc. for the year ended March 31, 2023.
/s/ Ernst & Young LLP
Iselin, New Jersey
May 22, 2023